Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. News
  7. Press Releases
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 10/25 06:43:44 am
6.592 GBX   -1.61%
04:44aSAREUM : Final Results
PU
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société SAREUM HOLDINGS PLC
04:44aSAREUM : Final Results
PU
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
09/29SAREUM : Reference to SRA737 Timeline at Cantor Conference
PU
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/19SAREUM : Subscription to raise £1,000,000
PU
07/01SAREUM : Completed Covid-19 Research Project Delivers Encouraging Results
PU
06/22SAREUM : to Present at BioTrinity 2021 Conference
PU
06/15SAREUM : Subscription to raise £1,470,000
PU
06/01SAREUM : Subscription to Raise £900,000
PU
05/25SAREUM : Trading Update
PU
05/13SAREUM : Exercise of Options and TVR
PU
04/23SAREUM : Half-year Report
PU
03/26SAREUM : Sareum Notes SRA737 Combination Data to be presented at the AACR Annual Meeting
AQ
03/25SAREUM : Research Update
PU
03/25SAREUM : Interim Results Extension
PU
02/16SAREUM : Notes New UK Government Covid-19 Initiative
PU
02/01SAREUM : to Present at the LSX World Congress 2021
PU
01/26SAREUM : to Participate in the Edison Open House
PU
01/11UPDATE RE : FLT3+Aurora Kinase Inhibitor Programme
PU
01/07SAREUM : US Patent Grant for TYK2/JAK1 Anticancer Candidate
PU
2020SAREUM : AGM Statement
AQ
2020SAREUM : AGM Statement
PU
2020SAREUM : Nature Article Highlights Role of TYK2 in Covid-19
PU
2020SAREUM : Covid-19 Research Grant Confirmed
PU
2020SAREUM : Notice of AGM
PU
2020SAREUM : Provides Update on Licensing Agreement Regarding SRA737, a Chk1 inhibitor in Clin..
AQ
2020SAREUM : Update on SRA737 Licensing Agreement
PU
2020SAREUM : Exercise of Share Options and Director Dealings
PU
2020SAREUM : Final results for the year ended 30 june 2020
AQ
2020SAREUM : Full Year Results Investor Presentation
PU
2020SAREUM : Final Results
PU
2020US PATENT ALLOWANCE : SDC-1802 TYK2/JAK1 Inhibitor
PU
2020SAREUM : Details of Investor Presentation
PU
2020SAREUM : Trading Statement
PU
2020SAREUM : Update on Deferred Salaries and Issue of Equity
PU
2020SAREUM : Successful Fundraising
PU
2020SAREUM : Placing to Raise £718,500
PU
2020SAREUM : to Present at BIO Bigital 2020
PU
2020SAREUM : BioTrinity Presentation Available Online
PU
2020SAREUM : Half-yearly results for the six months ended 31 december 2019
AQ
2020SAREUM : Half-year Report
PU
2019SAREUM : notes Sierra Oncology Q3 2019 Results
PU
2019SAREUM : Research Update - SDC-1802 Anti-Cancer Poster
PU
2019SAREUM : Research Update - AACR-NCI-EORTC abstract
PU
2019SAREUM : Final Results for the Year Ended 30 June 2018
PU
2019SAREUM : Notice of Full Year Results
PU
2019SAREUM : Research Update - TYK2/JAK1 Cancer Programme
PU
2019SAREUM : Change of Adviser
PU
2019SAREUM : notes Sierra Q2 results
PU
2019SAREUM : Additional disclosure concerning Michael Owen
PU
2019SAREUM : Additional Funds Raised
PU
2019SAREUM : Sierra Seeks Strategic Options for SRA737
PU
2019SAREUM : Successful Fundraising
PU
2019SAREUM : Placing to Progress TYK2/JAK1 Programmes
PU
2019SAREUM : PrimaryBid.com Offer
PU
2019SAREUM : Portfolio Update
PU
2019SAREUM : PLC Key Takeaways from SRA737 Webcast at ASCO
PU
2019SAREUM : Positive SRA737 Data Reported at ASCO
PU
2019SAREUM : ASCO Abstracts for SRA737 Published
PU
2019SAREUM : to Present at BioTrinity 2019 in London
PU
2019SAREUM : SRA737 Phase I/IIa data to be presented at ASCO
PU
2019SAREUM : Preclinical Data for SRA737 Presented at AACR 2019
PU
2019SAREUM : Issue of Options
PU
2018SAREUM : AGM Statement
PU
2018SAREUM : Preclinical Efficacy for Immunotherapy Combination
PU
2018SAREUM : Preclinical Data for SRA737 in Ovarian Cancer
PU
2018SAREUM : Sierra Oncology Q3 2018 Results
PU
2018SAREUM : Completion of Placing
PU
2018SAREUM : Final Results for the Year Ended 30 June 2018
PU
2018SAREUM : TYK2/JAK1 Selected for Certain Cancers
PU
2018SAREUM : Pre-Close Trading Statement
PU
2018SAREUM : Selection of TYK2/JAK1 for autoimmune diseases
PU
2018SAREUM : notes Sierra Oncology Q2 2018 Results
PU
2018SAREUM : Noticifation of PCA Shareholding
PU
1  2  3Next
Upcoming event on SAREUM HOLDINGS PLC
10/25/21